Image3

Image 1

Nvax 

Image 2

Logo NVAX

NVAX

Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for Ebola, influenza, respiratory syncytial virus (RSV), and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19. Novavax has indicated it recognizes a continued need for innovative vaccines in other therapeutic areas and reports it has taken steps to ensure continued advancement of its influenza vaccine.

Discover brands image

Collect rewards image

Connect Accounts image

Create profile image

Create a profile

How it works - Create a Profile

Connect accounts

How it works - Connect Accounts

Discover brands

How it works - Discover Brands

Collect rewards

How it works - Collect Rewards

TiiCKER offers a completely personalized experience and first-ever way to view your stock portfolio, trade for free and invest in new companies while viewing your perks in one place! 

How it works

Homepage - How It Works

TiiCKER was created for fan-first, brand-first public companies—with exclusive perks served-up weekly to shareholders. Own stock? Connect your brokerage account to view more than 130 perks waiting for you right now!  

Start earning perks <span>today</span>

Join Now CTA

## Congratulations! You *qualify* for a TiiCKER *perk*

## Congratulations! You *may qualify* for a TiiCKER *perk*

TiiCKER Perk CTA

Novavax, Inc. focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial. NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate, is in Phase 3 clinical trial. ResVax is a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.